The acute respiratory distress syndrome (ARDS) affects more than 190,000 patients each year in the US and continues to have a 30-40% mortality rate. Our research group recently reported that levels of cell-free hemoglobin (CFH) are elevated in pulmonary edema fluid from the distal airspaces of patients with ARDS and that increased airspace CFH is associated with increased alveolar-capillary permeability, suggesting that CFH may contribute to ARDS pathogenesis and may be a new target for ARDS therapy. The goals of this proposal are to advance our knowledge of the cellular and molecular consequences of CFH in the airspace and test a CFH-targeted therapy in the airspace. Our preliminary data establish a unique model system that we will harness to define the proximal regulators of acute inflammation in the lung. Instillation of purified endotoxin- free CFH into the airspace of mice is sufficient to induce robust alveolar inflammation and has identified alveolar macrophages as a key target of CFH. Furthermore, mice deficient in TLR4 have attenuated inflammation in response to CFH, identifying one key pathway in its mechanism. We also have determined that CFH is engulfed by only a subpopulation of macrophages in the airspace and that these CFH-containing macrophages have less pro-inflammatory cytokine production than cells lacking CFH. Based on these data, we propose that intra-alveolar CFH may modulate both pro- and anti-inflammatory pathways during acute lung injury and that the balance between these pathways could be manipulated in the airspace as a novel therapy for ARDS. In this proposal, we will test the hypothesis that CFH causes airspace inflammation through TLR4- dependent NF-?B activation in alveolar macrophages and that augmentation of CFH uptake into macrophages with haptoglobin will ameliorate acute lung injury through attenuation of macrophage-dependent inflammation.
In Aim 1, we will use transgenic mice with macrophage-specific TLR4 deletion or NF-?B inhibition to determine the role of macrophage TLR4 and NF-?B activation in CFH-mediated airspace inflammation.
In Aim 2, we will use CD163 null mice and a novel application of magnetic cell sorting to determine whether uptake of CFH into alveolar macrophages alters macrophage polarization towards an anti-inflammatory state.
In Aim 3, we will test intra-alveolar haptoglobin as a new therapy for ARDS using a mouse model of bacterial pneumonia and will determine the clinical importance of haptoglobin in the airspace during ARDS. By the completion of these studies, we will have identified the cell-specific and molecular mechanisms of a novel mediator of ARDS and tested a new localized ARDS therapy that has high potential for rapid translation into human clinical trials. In addition, through these studies, a promising young physician scientist will gain new skills in basic and translational studies of ARDS under the guidance of a highly accomplished mentorship committee of experts in ARDS, inflammation, and macrophage biology. These new mentored skills will form the foundation for this junior investigator to achieve a long-term goal to be an independently funded academic physician scientist.

Public Health Relevance

Cell-free hemoglobin has been recently identified as a novel contributor to lung injury in patients with the acute respiratory distress syndrome (ARDS). In this proposal, we will perform experiments in mice, cell culture, and samples from human lungs to determine how cell-free hemoglobin alters alveolar macrophage biology to cause increased lung inflammation and will test whether hemoglobin-targeted therapy can limit lung injury by removing cell-free hemoglobin from the airspace, identifying a potential new therapy for ARDS.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Clinical Investigator Award (CIA) (K08)
Project #
5K08HL136888-04
Application #
9922346
Study Section
NHLBI Mentored Clinical and Basic Science Review Committee (MCBS)
Program Officer
Reineck, Lora A
Project Start
2017-05-01
Project End
2022-04-30
Budget Start
2020-05-01
Budget End
2021-04-30
Support Year
4
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Vanderbilt University Medical Center
Department
Type
DUNS #
079917897
City
Nashville
State
TN
Country
United States
Zip Code
37232
McNeil, J Brennan; Shaver, Ciara M; Kerchberger, V Eric et al. (2018) Novel Method for Noninvasive Sampling of the Distal Airspace in Acute Respiratory Distress Syndrome. Am J Respir Crit Care Med 197:1027-1035
Shaver, Ciara M; Wickersham, Nancy; McNeil, J Brennan et al. (2018) Cell-free hemoglobin promotes primary graft dysfunction through oxidative lung endothelial injury. JCI Insight 3:
Shaver, Ciara M; Wickersham, Nancy; McNeil, J Brennan et al. (2017) Cell-Free Hemoglobin-mediated Increases in Vascular Permeability. A Novel Mechanism of Primary Graft Dysfunction and a New Therapeutic Target. Ann Am Thorac Soc 14:S251-S252